Early changes in myocardial stunning and biomarkers after ST-elevation myocardial infarction compared to the takotsubo syndrome

Abstract Background Takotsubo syndrome (TS) and ST-elevation myocardial infarction (STEMI) are both characterized by sudden cessation of contractions (myocardial stunning) as well elevation cardiac troponins B-type natriuretic peptides (BNP). Whereas STEMI results in variable degrees necrosis persistent dysfunction, TS little to any full recovery function. No “head-to-head” comparison the temporal resolution stunning serum biomarkers versus takotsubo has been done. Purpose To compare time course function over acute subacute phases STEMI, with patients further subdivided into anterior non-anterior STEMI. Method The Stunning In Acute Myocardial Infarction (STAMI) study is a prospective, multi-center that enrolls or without known pre-existing dysfunction. Echocardiography, laboratory testing (including NT-proBNP), ECG acquired within 4 hours after coronary angiography at 24±6, 48±12, 72±12 7±1, 14±2, 30±2 days. primary endpoint proportion reversible akinesia resolved 72 (Figure 1), determined echocardiography. Secondary endpoints include troponin-I, troponin-T, NT-proBNP. Results Preliminary from 155 (78 77 STEMI) 32 presented Figure 1. Mean (SD) age was similar for (67±14), (68±11), (68±10). All 3 groups showed substantial study, most pronounced TS. Compared groups, group also had lower troponin-I troponin-T ratio, higher NT-proBNP 2). recovered TS, (p=0.8414). Conclusion STAMI will provide comprehensive assessment biomarker profile early disease. data suggest functional more but follows time-course differences magnitude troponin were than T. Funding Acknowledgement Type funding sources: Public grant(s) – EU funding. Main source(s): ERC - European Research Council